AWS partners with Pfizer to accelerate drug development
Biotech

AWS partners with Pfizer to accelerate drug development

It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies

  • By IPP Bureau | December 06, 2021

Amazon Web Services (AWS), said it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. The companies are exploring these advances through their newly created Pfizer Amazon Collaboration Team (PACT) initiative, which applies AWS capabilities in analytics, machine learning, compute, storage, security, and cloud data warehousing to Pfizer laboratory, clinical manufacturing and clinical supply chain efforts.

 For instance, AWS is helping Pfizer enhance its continuous clinical manufacturing processes by incorporating predictive maintenance capabilities built with AWS machine learning services like Amazon Lookout for Equipment (AWS’s service for detecting abnormal equipment behaviour by analyzing sensor data). As a result, Pfizer can maximize uptime for equipment such as centrifuges, agitators, pulverizers, coaters, and air handlers used in clinical drug manufacturing. The overall focus of this collaboration is to support Pfizer in more rapidly and reliably producing new drugs and evaluating their potential health benefit for patients.

“Our life sciences customers are increasingly looking for opportunities to scale expertise, insight, and secure access to the right information, at the right time, with the aim of reducing the time and cost for drug development and clinical trials,” said Kathrin Buvac, Vice President of Business Development and Industries at Amazon Web Services, Inc. “AWS’s breadth and depth of cloud capabilities help support Pfizer’s teams through secure, novel research methods as they work to optimize drug development and clinical manufacturing processes.’’

“Pfizer’s goal with AWS is to expedite the processes for drug discovery and development in ways that can ultimately enhance patient experiences and deliver new therapies to market. Working closely with AWS experts in machine learning and analytics, we aim to provide our scientists and researchers with the insights they need to help deliver medical breakthroughs that change patients’ lives,” said Andrew McKillop, Vice President of Pharmaceutical Sciences, Worldwide Research, Development, and Medical at Pfizer.

AWS is working with Pfizer to develop a prototype solution for detecting abnormal data points in its drug product continuous clinical manufacturing platform for solid oral-dose medicines. The prototype solution is built using Amazon SageMaker (AWS’s service for building, training, and deploying machine learning models quickly in the cloud and at the edge), Amazon Lookout for Equipment, Amazon Lookout for Metrics (AWS’s service for automatically detecting anomalies in metrics and identifying their root cause), and Amazon QuickSight (AWS’s scalable machine learning-powered business intelligence service for the cloud). The machine learning models used in the prototype were able to provide early warnings for alarms with minimal false positives, and direct users to the relevant signals. As a result, Pfizer can process data from the equipment and sensors involved in Portable Continuous Miniature and Modular (PCMM) manufacturing to detect anomalies as they occur, predict maintenance needs, and reduce potential equipment downtime.

 

Upcoming E-conference

Other Related stories

Startup

Digitization